We reason that potent PAR-2 antagonists/inhibitors may provide chemotherapeutic sensitization in cancer patients by blocking trypsin mediated survival signaling and sensitizing cells to other apoptosis inducing compounds such as chemotheraputic agents. This evidence concerns the gene F2RL1 and cancer.